1219. Unfavorable Clinical Outcomes with Polymyxins Compared to Ceftolozane/Tazobactam for the Treatment of Carbapenem-Resistant Pseudomonas aeruginosa

BACKGROUND: Patients with carbapenem-resistant Pseudomonas aeruginosa (CRPA) have high in-hospital mortality rates. It is unknown if patients with CRPA treated with ceftolozane/tazobactam (C/T) have improved clinical outcomes compared to those treated with polymyxins. METHODS: The CDC-funded, Georgi...

Descripción completa

Detalles Bibliográficos
Autores principales: Howard-Anderson, Jessica, Earley, Michelle, Hamasaki, Toshimitsu, Bower, Chris W, Smith, Gillian, van Duin, David, Evans, Scott R, Jacob, Jesse T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643759/
http://dx.doi.org/10.1093/ofid/ofab466.1411

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643759/
http://dx.doi.org/10.1093/ofid/ofab466.1411

Ejemplares similares